Common stock: Par value $.001
- Symbol
- RNTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Rein Therapeutics, Inc.
RNTXNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 4, 2026, Rein Therapeutics, Inc. (“Company”) published a presentation concerning its LTI-03 product candidate on its website at https://ir.reintx.com/events-presentations. A copy of the presentation is attached as Exhibit 99.1 hereto.…
Company context
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. Our lead product candidate is LTI-03, a peptide for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis that has demonstrated the ability in both preclinical studies and clinical trials to protect healthy lung epithelial cells and reduce pro-fibrotic signaling. Our second product candidate is LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion patients, an indication that has no approved drug treatment. In June 2024, we decided to temporarily delay clinical development of LTI-01 in an effort to focus our resources on clinical development of LTI-03 and until additional funds are raised. In the fourth quarter of 2025, we decided to pause development activities related to LTI-01, preclinical programs targeting cystic fibrosis and a peptide program focused on the Cav1 protein for an indefinite period.
Current securities
Historical securities (1)
Recent company filings
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 27, 2026
- SCHEDULE 13G/A - filed by Lynwood Capital Management Inc. regarding Rein Therapeutics, Inc.Aug 14, 2026
- 10-Q filingAug 14, 2026
- Submission of Matters to a Vote of Security HoldersJul 21, 2026
- SCHEDULE 13G/A - filed by Voss Capital, LP regarding Rein Therapeutics, Inc.Jul 14, 2026
Registered securities in this filing
REIN THERAPEUTICS, INC. · 8-K · Filed 2026-09-04
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On September 4, 2026, Rein Therapeutics, Inc. (“Company”) published a presentation concerning its LTI-03 product candidate on its website at https://ir.reintx.com/events-presentations. A copy of the presentation is attached as Exhibit 99.1 hereto.
The information in this Item 7.01, including the presentation attached as Exhibit 99.1, are furnished pursuant to Item 7.01 but shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall either be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 2 d111215dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Harnessing fibrosis, unleashing life Science Deck| September 2026 Copyright © 2026 Rein Therapeutics Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the expected benefits of using CSDs for fibrotic indications and our plans to develop and commercialize LTI-03, including the potential benefits thereof. We use words such as “anticipate,” ”believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including (i) the risk that the Company may not be able to successfu…
Open exhibit ↗